hemochromatosis

hemochromatosis. It is a disorder of iron metabolism characterized by excessive intestinal absorption of iron, leading to its pathological accumulation in various organs. This iron overload can cause severe damage to the liver, heart, pancreas, and endocrine glands. The condition is one of the most common genetic disorders among individuals of Northern European descent. If untreated, the accumulated iron results in organ failure and increased mortality.

Signs and symptoms

Early stages are often asymptomatic, with iron accumulation occurring gradually over decades. Initial nonspecific complaints may include fatigue, joint pain, and Abdominal pain. As iron deposition progresses, organ-specific manifestations develop. Classic findings include bronze or slate-gray skin discoloration, a consequence of Melanin and iron deposition, and Diabetes mellitus from pancreatic Beta cell destruction, historically termed "bronze diabetes." Cardiomyopathy with Heart failure or Arrhythmia can occur due to myocardial iron deposition. Hypogonadism is common, often presenting as Loss of libido or Amenorrhea from pituitary involvement. Arthritis, particularly affecting the second and third metacarpophalangeal joints, is a frequent and sometimes debilitating feature.

Causes

The vast majority of cases are hereditary, caused by mutations in genes involved in iron homeostasis. The most common form is **HFE-related** hemochromatosis, an Autosomal recessive disorder primarily associated with mutations in the HFE gene on chromosome 7; the C282Y mutation is most prevalent, especially in populations from Celtic and Scandinavian origins. Compound heterozygosity for C282Y and H63D is also a known genetic risk. Non-HFE forms are rarer and often present earlier. These include mutations in the Hemojuvelin gene (leading to severe juvenile onset), the Transferrin receptor 2 gene, and the Ferroportin gene. Secondary hemochromatosis can result from chronic conditions requiring frequent Blood transfusions, such as Beta thalassemia major or Myelodysplastic syndrome.

Pathophysiology

The fundamental defect lies in the dysregulation of Hepcidin, the master iron regulatory hormone produced by the Liver. In HFE-related disease, mutations impair the signaling pathway that normally increases hepcidin synthesis in response to elevated iron stores. Low circulating hepcidin levels fail to inhibit the iron exporter Ferroportin on intestinal enterocytes and macrophages. This leads to unabated dietary iron absorption and excessive release of recycled iron from the Reticuloendothelial system. The body lacks an active excretory mechanism for iron, so the surplus circulates bound to Transferrin and is deposited as Hemosiderin in parenchymal cells of target organs. Within cells, iron catalyzes the formation of reactive oxygen species via the Fenton reaction, causing Lipid peroxidation, protein modification, and DNA damage, ultimately resulting in cellular injury, Fibrosis, and organ dysfunction.

Diagnosis

Diagnosis involves a combination of biochemical testing, genetic analysis, and assessment of organ iron burden. Initial screening tests measure Transferrin saturation and Serum ferritin; persistently elevated transferrin saturation (>45%) is a sensitive early indicator. Elevated ferritin reflects increased iron stores but can also be raised in inflammatory conditions like Rheumatoid arthritis. Confirmation of iron overload typically involves Liver biopsy with quantitative iron measurement and histological staining for iron (Perls' Prussian blue), which remains the diagnostic gold standard for assessing hepatic fibrosis. Non-invasive methods like Magnetic resonance imaging (specifically T2* and R2* sequences) are increasingly used to quantify hepatic and cardiac iron concentration. Genetic testing for **HFE** mutations (C282Y, H63D) is performed to confirm hereditary hemochromatosis, especially in individuals of European ancestry.

Treatment

The primary and most effective treatment is therapeutic Phlebotomy, which mimics blood donation to remove excess iron. An initial induction phase involves weekly removal of 500 mL of blood until ferritin levels are reduced to a low-normal range, often monitored through regular Complete blood count checks. This is followed by a lifelong maintenance schedule of phlebotomies every 2–4 months to keep ferritin levels stable. For patients who cannot tolerate phlebotomy due to severe Anemia or Hypoproteinemia, iron chelation therapy is used. Chelating agents such as subcutaneous Deferoxamine or oral Deferasirox and Deferiprone bind excess iron and promote its urinary or fecal excretion. Management also includes treating complications: screening for and managing Hepatocellular carcinoma in patients with Cirrhosis, controlling Diabetes mellitus, and addressing Heart failure or Hypogonadism with hormone replacement.

Prognosis

The prognosis is excellent if the diagnosis is made and treatment is initiated in the pre-cirrhotic stage, with a normal life expectancy. Regular phlebotomy can prevent further organ damage and may reverse some early manifestations like fatigue and mild hepatic dysfunction. However, established organ damage is often irreversible. The presence of Cirrhosis at diagnosis significantly worsens the outlook, increasing the risk of life-threatening complications such as Liver failure and Hepatocellular carcinoma, necessitating surveillance with ultrasound. Cardiomyopathy from iron overload, if severe, carries a poor prognosis but may improve with aggressive iron removal. With appropriate management, most patients avoid major disability and maintain a good quality of life. Category:Genetic disorders Category:Metabolic disorders Category:Hepatology